Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-09-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and contains a notification regarding 'Voting rights and capital' as of a specific date (31 August 2021), referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of announcement, which reports on the total number of voting rights, fits the definition of a general regulatory announcement that doesn't fit a more specific financial report category. Although it relates to capital structure, it is a mandatory disclosure under transparency rules rather than a financing activity (CAP) or share issue (SHA). Given the source (RNS) and the nature of the disclosure (voting rights notification), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such mandatory regulatory updates.
2021-09-01 English
FORXIGA APPROVED IN JAPAN FOR CKD
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Forxiga in Japan for chronic kidney disease, including clinical trial results, drug indications, and company background. The document is not an annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information about a product approval and related clinical data. The document length is over 12,000 characters and contains substantive content, not just an announcement of a report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2021-08-26 English
ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting on a clinical trial result (ALXN1840 Wilson Phase III met primary endpoint). Form 6-K is a report of foreign issuer pursuant to the Securities Exchange Act of 1934, typically used to disclose material information between annual reports (20-F). The content is a detailed announcement of clinical trial results and related information, not a full annual or interim financial report, nor an earnings release or management discussion. It is not a proxy, voting result, or governance document. The document length is 8772 characters, which is substantial but the content is primarily a clinical trial result announcement rather than financial data or management analysis. This type of filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement by a foreign issuer that does not fit into other specific categories such as Annual Report, Earnings Release, or Investor Presentation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-08-26 English
Forxiga approved in Japan for CKD
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement distributed via the RNS service of the London Stock Exchange. The content details a specific regulatory event: the approval of the drug Forxiga in Japan by the Ministry of Health, Labour and Welfare (MHLW). This is a material corporate event announcement, not a full financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a general regulatory announcement that doesn't fit into the more specific categories like Director's Dealing (DIRS) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS.
2021-08-26 English
ALXN1840 Wilson Phase III met primary endpoint
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number' and is dated August 26, 2021. It details positive Phase III clinical trial results for a drug (ALXN1840) in Wilson disease, including statistical endpoints, management commentary, and future submission plans. This format—a brief announcement of significant, non-periodic operational/clinical news, often disseminated via an official news service like RNS—is characteristic of a general regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific shareholder action (DIV, DVA), the most appropriate classification is the general regulatory filing category, RNS, as it serves as a primary information provider announcement.
2021-08-26 English
UPDATE ON ULTOMIRIS PHASE III ALS TRIAL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides an update on the discontinuation of the CHAMPION-ALS Phase III clinical trial of Ultomiris due to lack of efficacy, including detailed clinical trial information and company statements. The document does not contain comprehensive financial statements or detailed financial performance data typical of an Annual or Interim Report. It is not a transcript, capital update, or governance information. The document is a regulatory announcement providing material information about a clinical trial update, which fits the category of Regulatory Filings (RNS) as it does not fit into more specific categories and is a general regulatory announcement.
2021-08-20 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.